![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, February 03, 2009 2:02:50 PM
http://www.dnaprint.com/welcome/corporate/
Relevant excerpt:
Pharmacogenomics Market - The testing of individuals to predict their genetic predisposition to drug response is known as pharmacogenomics. Pharmacogenomics enables physicians to tailor drug therapies (formulation and dosage) for individuals based on their genetic composition, increasing rates of therapeutic success and decreasing rates of adverse side effects. Drug discovery companies are beginning to use pharmacogenomics technologies to develop drugs that are suitable for subpopulations based upon their genetic composition. We at DNAPrint® believe that as doctors and health care providers have been reporting for thousands of years; that different peoples from different countries have variable responses to medications is reason enough for us to explore this realm of medicine. We hope to be able to help predict whether a woman taking a chemotherapy agent for a cancer will respond favorably to a drug. We also will apply our technology to our own therapeutics, such as PT-401 a ‘super EPO’. This will help improve the efficacy of the drug therapy going into clinical evaluation as well as helping to improve and maintain patient response efficacy after the drug is approved. Pharmaceutical and pharmaceutical diagnostics are important cornerstones for our future value to our shareholders. We believe individualized medicine, while still some years away, will be here to stay, especially now that the U.S. FDA has written about pharmacogenomics. view PDF
http://www.dnaprint.com/welcome/pdf/2003d-0497-gdl0002.pdf
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM